Market News

Altimmune Tanks on Pemvidutide Interim data in Obesity and Type 2 Diabetes

Shares of biopharmaceutical company Altimmune (NASDAQ:ALT) are in a freefall today after it announced interim data evaluating pemvidutide in a Phase 2 study in obesity and a Phase 1b study in Type 2 diabetes and obesity.

In the Phase 2 study, the therapy showed a mean weight loss of 11.9% in participants weighing 115kg or less and about 50% of participants witnessed 10% or higher weight loss. Further, robust declines were seen in waist circumference, serum lipids, and blood pressure without a significant uptick in heart rate.

In the Phase 1b trial in type 2 diabetes, excellent tolerability was observed with 7.7% weight loss at 2.4mg dosing. Next, the company expects the 48-week obesity trial to end in Q4 2023 and anticipates beginning a phase 2 biopsy NASH trial in the middle of this year.

Overall, Wall Street has a consensus price target of $29.13 on ALT, implying a mouth-watering 456% potential upside in the stock. But that’s after a nearly 52.6% slide in the share price over the past month. At the same time, short interest in the stock remains high at about 16% at present.

Read full Disclosure

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More